Lercanidipin Accord (Lercanidipine Hydrochloride)

Lercanidipine is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure. It works within the vascular system to achieve blood‑pressure control.

• Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension.
• Isolated systolic hypertension: lowers elevated systolic pressure in older adults.
• Secondary hypertension: assists in blood‑pressure control when hypertension is due to identifiable causes.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for contraction. This inhibition leads to relaxation of arterial smooth muscle, resulting in vasodilation and a consequent reduction in peripheral vascular resistance and arterial blood pressure.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate headache occurring shortly after dosing.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Tachycardia: increased heart rate.
• Palpitations: awareness of heart beating.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, pruritus, or angioedema.
• Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use with caution in patients with liver disease.
• Concomitant antihypertensives: adjust doses to prevent additive effects.
• Sudden discontinuation: avoid abrupt stopping to reduce rebound hypertension.
• Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Grapefruit juice: can markedly raise drug levels.
• Other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness.
• Diuretics: may enhance antihypertensive effect.
• Beta‑blockers: combined use may require dose adjustments.
• NSAIDs: can attenuate blood‑pressure‑lowering effect.